Capecitabine-induced multifocal leukoencephalopathy: a report of five cases

A Videnovic; I Semenov; R Chua-Adajar; L Baddi; D T Blumenthal; A C Beck; T Simuni; S Futterer; W Gradishar; C Tellez; J J Raizer

doi:10.1212/01.wnl.0000187313.83515.7e

Capecitabine-induced multifocal leukoencephalopathy: a report of five cases

Neurology. 2005 Dec 13;65(11):1792-4; discussion 1685. doi: 10.1212/01.wnl.0000187313.83515.7e. Epub 2005 Oct 19.

Authors

A Videnovic¹, I Semenov, R Chua-Adajar, L Baddi, D T Blumenthal, A C Beck, T Simuni, S Futterer, W Gradishar, C Tellez, J J Raizer

Affiliation

¹ Davee Department of Neurology and Neurological Sciences, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.

PMID: 16237130
DOI: 10.1212/01.wnl.0000187313.83515.7e

Abstract

Capecitabine is used to treat advanced breast and gastrointestinal malignancies. A single case of encephalopathy and three cases of peripheral neuropathy are the only neurotoxicities reported. The authors report five additional cases of capecitabine-induced multifocal leukoencephalopathy.

Publication types

Case Reports

MeSH terms

Adult
Aged
Antimetabolites, Antineoplastic / adverse effects*
Brain / drug effects*
Brain / pathology*
Brain / physiopathology
Breast Neoplasms / drug therapy
Capecitabine
Carcinoma / drug therapy
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives*
Female
Fluorouracil / analogs & derivatives
Humans
Magnetic Resonance Imaging
Middle Aged
Neoplasm Metastasis / drug therapy
Neurotoxicity Syndromes / diagnosis*
Neurotoxicity Syndromes / physiopathology
Pancreatic Neoplasms / drug therapy
Withholding Treatment

Substances

Antimetabolites, Antineoplastic
Deoxycytidine
Capecitabine
Fluorouracil